nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.12.2019 | editorial

An update from the 2019 ASCO Annual Meeting

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Excerpt

For decades, the American Society of Clinical Oncology (ASCO) Annual Meeting has been regarded as the most eminent oncology congress and a multitude of practice-changing trials reported their results at this meeting. While this has somewhat changed just recently with the European Society of Medical Oncology (ESMO) conference gaining relevance, news from the ASCO Annual Meeting is still of great clinical importance as outlined in this series of short reviews. …

Nächster Artikel Amazing advances in the field of uro-oncology

Wass RE, Lang D, Lamprecht B, Studnicka M. Targeted therapy in lung cancer — ASCO 2019 update. memo. 2019. https://doi.org/10.1007/s12254-019-00538-3.CrossRef

Dediu M. Current trends in small cell lung cancer management — ASCO 2019 update. memo. 2019. https://doi.org/10.1007/s12254-019-00539-2.CrossRef

Beslija S. ASCO 2019 — Personal highlights on adjuvant breast cancer: (neo-)adjuvant therapy of HER2-negative HR-positive BC. memo. 2019. https://doi.org/10.1007/s12254-019-00546-3.CrossRef

Suppan C, Balic M. Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer. The best of ASCO 2019. memo. 2019. https://doi.org/10.1007/s12254-019-00530-x.CrossRef

Bartsch R, Bergen E. ASCO 2019: highlights in HER2-positive metastatic breast cancer. memo. 2019. https://doi.org/10.1007/s12254-019-00543-6.CrossRef

Titel: An update from the 2019 ASCO Annual Meeting
Publikationsdatum: 01.12.2019
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-019-00544-5

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

Targeted therapy in lung cancer—ASCO 2019 update

Surgery in renal cell carcinoma—when, whom and how?

Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer

Neoadjuvant therapy in urothelial cancer

First-line treatment of metastatic renal cell carcinoma: current standard of care

HPV-associated cancers